ZoetisRegister for a premium account to gain access to Sterling AI.
Get StartedThings you can ask Sterling:
Zoetis (ZTS) reported revenue of $2.47B in Q2 2026, with Dogs and Cats its largest revenue segment at 68%.
ZoetisZoetis develops and sells medicines, vaccines, and diagnostics for companion animals and livestock. Companion-animal products were about 70% of 2025 revenue.
Zoetis (ZTS) is a Pharmaceuticals company. Zoetis develops and sells medicines, vaccines, and diagnostics for companion animals and livestock. Companion-animal products were about 70% of 2025 revenue. It was founded in 1952, is headquartered in Parsippany, New Jersey and employs about 14,500 people.
As of 2026-Q2, Zoetis's revenue breaks down across Dogs and Cats (68%), Cattle (16%), Swine (5%), Poultry (5%). See the revenue-by-segment chart for the full mix.
Track Zoetis's quarterly and annual revenue, gross and net margins, and EPS in the interactive charts on this page. Data last updated October 10, 2026.
Sterling groups Zoetis in the Healthcare industry, alongside Bristol Myers Squibb (BMY), Johnson & Johnson (JNJ) and Viatris (VTRS).
If you are researching Zoetis, also look at Bristol Myers Squibb (BMY), Johnson & Johnson (JNJ) and Viatris (VTRS). You can compare all of them side by side or browse the full Healthcare industry on Sterling.
Q3 2016-Q2 2026
Q3 2016-Q2 2026